The board of directors of Antengene Corporation Limited announced that the company's first-in-class new drug, selinexor has been successfully included in the 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023 NRDL), with the scope of coverage being "limited to adult patients with relapsed and/or refractory multiple myeloma who have received prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody". The 2023 NRDL will officially come into effect on January 1, 2024. XPOVIO® was approved for marketing in China in December 2021.

XPOVIO® is the world's first and only orally-available, selective inhibitor of the nuclear export protein XPO1 that has obtained approval for marketing. Inclusion in the 2023 NRDL will further improve the accessibility and affordability of XPOVIO® to address the unmet medical needs of more patients with relapsed and/or refractory multiple myeloma.